OncoMatch

OncoMatch/Clinical Trials/NCT05123365

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Is NCT05123365 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies N-Acetylcysteine for myeloproliferative neoplasm.

Phase 1/2RecruitingUniversity of California, IrvineNCT05123365Data as of May 2026

Treatment: N-Acetylcysteine — This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients with myeloproliferative neoplasms (MPN).

Check if I qualify

Extracted eligibility criteria

Cancer type

Myeloproliferative Neoplasm

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: interferon-alpha

Has not taken interferon-alpha...for treatment of MPN in the past 28 days before enrollment.

Cannot have received: JAK inhibitor (ruxolitinib, fedratinib)

Has not taken...a JAK inhibitor (such as ruxolitinib or fedratinib) for treatment of MPN in the past 28 days before enrollment.

Cannot have received: (N-Acetylcysteine)

Has not taken N-Acetylcysteine (N-AC) or preparations containing N-AC in the past 28 days before enrollment.

Lab requirements

Blood counts

Platelets < 100 × 10^9/L; Hgb < 10 g/dL; ANC < 0.75 × 10^9/L

Kidney function

Serum creatinine clearance less than 50 ml/min (calculated with Cockroft-Gault formula).

Liver function

Bilirubin more than 1.5 mg/dl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis.

Significant impairment of major organ function defined as: 1. Serum creatinine clearance less than 50 ml/min (calculated with Cockroft-Gault formula). 2. Bilirubin more than 1.5 mg/dl except for Gilbert's disease. ALT or AST more than 2X upper normal limit or has radiologic evidence of liver cirrhosis. 3. Platelets < 100 × 10^9/L 4. Hgb < 10 g/dL 5. ANC < 0.75 × 10^9/L

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of California, Irvine · Irvine, California
  • Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify